Medrad announced this month that its president and CEO Thomas Witmer is planning to retire. Witmer has led the Indianola, PA, manufacturer of contrast injection systems for the last 16 years, and saw the company through its acquisition by German contrast
Medrad announced this month that its president and CEO Thomas Witmer is planning to retire. Witmer has led the Indianola, PA, manufacturer of contrast injection systems for the last 16 years, and saw the company through its acquisition by German contrast agent developer Schering in 1995 (SCAN 8/30/95). Medrad senior vice president and general manager John Friel has been tapped to replace Witmer as president and CEO in a transition process to be phased in over the next several months. Witmer will remain on Medrad's board.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.